Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Summary

The objective of this study is to evaluate the comparative bioavailability between bupropion hydrochloride 300 mg extended release tablets (Teva Pharmaceuticals USA) and Wellbutrin XL® 300 mg extended release tablets (Biovail Pharmaceuticals, Inc.) at steady-state in patients under fasting conditions.

Timeline

Start

2010-01

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment issues”

Drugs

Indications